Exact Sciences Receives Nasdaq Delisting Notice; Plans to Appeal | GenomeWeb
NEW YORK (GenomeWeb News) – Exact Sciences has received notice from the Nasdaq Stock Market indicating that its stock is subject to delisting because it has not regained compliance with exchange’s requirement of a minimum $50 million market capitalization.
 
Exact said today that it received the letter from the Nasdaq’s Listing Qualifications Staff on Aug. 12.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.